Biodexa Pharmaceuticals (BDRX) Assets (2013 - 2025)

Biodexa Pharmaceuticals has disclosed Assets across 13 years of filings, most recently posting $24.2 million for Q4 2025.

• In Q4 2025, Assets rose 27.47% year-over-year to $24.2 million; the TTM figure through Dec 2025 stood at $24.2 million (up 27.47% YoY), while the FY2025 annual figure was $24.0 million, up 26.87% from the prior year.
• Assets came in at $24.2 million for Q4 2025 at Biodexa Pharmaceuticals, up from $19.8 million in the prior quarter.
• In the past five years, Assets ranged from a high of $24.2 million in Q4 2025 to a low of $6.5 million in Q4 2022.
• Average Assets over 5 years is $15.1 million, with a median of $15.2 million recorded in 2021.
• Year-over-year, Assets sank 62.77% in 2022 and surged 101.9% in 2023.
• Over 5 years, Assets stood at $17.4 million in 2021, then slumped by 62.77% to $6.5 million in 2022, then jumped by 101.9% to $13.1 million in 2023, then jumped by 44.98% to $19.0 million in 2024, then gained by 27.47% to $24.2 million in 2025.
• Per Business Quant data, the three most recent Assets figures were $24.2 million in Q4 2025, $19.8 million in Q2 2025, and $19.0 million in Q4 2024.